Login
ELUTIA INC. logo

ELUTIA INC.

Compare classes
elutia.com

What Do They Do?

Sells biologic matrix products for soft-tissue reconstruction and cardiovascular repair to healthcare facilities, and develops drug-eluting biomatrix products for reconstructive surgery.

How Do They Make Money?

Women’s Health was 74% of revenue; healthcare facilities buy SimpliDerm, with sales earning revenue when products ship or are delivered, or when consigned stock is used or implanted.

revenue
SegmentShareRevenue
Women's Health
Sold outright

74%
Cardiovascular
Sold outright

26%

Who Are Their Customers?

SimpliDerm is sold to plastic and reconstructive surgeons through independent sales agents; cardiovascular products go to hospitals and other healthcare facilities through independent sales agents.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2024: 23% from two customers

Do Revenues Turn Into Profits?

Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$46.7M.

Operating income, FY2025
−219% of revenue
▲ +12% (Loss) vs FY2024 (−$30.7M, −212%)
Net income, FY2025
434% of revenue
▲ Turned profitable vs FY2024 (−$53.9M, −373%)
Free cash flow, FY2025
−380% of revenue
▼ −100% (Loss) vs FY2024 (−$23.3M, −161%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +20%
vs $944K in Q3 FY2025
Net income
▲ +67% (Loss)
vs −$3.9M in Q3 FY2025
  • Aug 21, 2026 Sold the SimpliDerm business The sale closed for $7.7 million, with possible additional contingent payments tied to milestones.
  • Aug 7, 2026 Received a Nasdaq minimum-bid-price deficiency notice Nasdaq gave the company until February 2, 2027 to regain compliance; its stock continued trading during the compliance period.

Shrinking. Revenue fell 74% in 4 years, from $47.4M in FY2021 to $12.3M in FY2025, about 29% a year.

Narrower product portfolio The earlier report described products across device protection, women’s health, orthobiologics and cardiovascular markets. The latest report describes a focus on drug-eluting biomatrix development, alongside commercial products for reconstructive and cardiovascular repair.

Reconstructive development focus The earlier report planned an antibacterial device-protection pouch and candidates for device protection, women’s health and orthobiologics; the latest centers development on drug-eluting biomatrices for reconstructive surgery.

Sales channel The earlier report described a mix of a direct sales force, commercial partners and independent sales agents. The latest report says its commercial products are sold through independent sales agents.

Revenue over time
Women's Health Cardiovascular Device Protection
$25M$12.5M$0

Who Do They Compete With?

Competes with Gore, Terumo, AbbVie, MTF, Stryker, Evergen, and Integra

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support